Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe page revision updated from v3.5.3 to v3.5.4, signaling a new build deployment. This update does not modify the study content or essential information on the page.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedVersion label updated from v3.5.2 to v3.5.3, signaling a new release of the page interface. The update does not modify the study content or data.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision added: v3.5.0; revision v3.4.3 removed.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be an internal version update with no changes to study content or eligibility.SummaryDifference0.1%

- Check100 days agoChange DetectedRevision: v3.4.2 has been added to the page. The prior government funding/operating status notice (v3.4.1) has been removed.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.